Clinical trial · Interventional
Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the present feasibility study of a new short palliative radiotherapy regime that apply to patients with metastatic hormone refractory prostate cancer (HRPC) presenting with a dominating debilitating symptom. Diffusion weighted magnetic resonance imaging (DWI) will apply to identify both the lesion and the most aggressive part of the lesion. The symptomatic lesions will be treated with a dose of 4 x 5 Gy, while for the most aggressive part of the lesion the dose will be escalated to 4 x 7 Gy using a simultaneous integrated boost (SIB) technique.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hormone-refractory Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Palliative radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- feasibilty
- description
- Palliative Radiotherapy
- interventionNames
- Radiation: Palliative radiotherapy
Primary outcomes (1)
- measure
- Proportion of study participants that complete the study
- timeFrame
- 6 months
- description
- Proportion of study participants that complete radiotherapy with ≥ 90% of prescribed dose
Secondary outcomes (3)
- measure
- Response in dominating symptom score (short form McGill pain Questionnaire)
- timeFrame
- Baseline, 1,3 and 6 months after radiotherapy
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with hormone refractory biopsy proven prostate cancer 2. Presenting with a dominating debilitating symptom 3. Expected median survival of 12 months 4. Focal irradiation of lesion is feasible 5. Systemic therapy according to guidelines 6. age ≥18 years 7. Legal capacity, able to understand consequences of the trial 8. Written informed consent Exclusion Criteria: 1. Relevant comorbidity (limiting radiotherapy according to protocol) 2. Prior radiotherapy limitations to administer radiotherapy according to protocol 3. No large metal implants in vicinity of lesion 4. Department dose constraints for normal tissue can't be met 5. Large bony lesions with extensive osseous destruction 6. Patients symptoms do not correlate with MR findings
References
Publications (1)
- DERIVEDCarl J, Rades D, Doemer C, Setter C, Dunst J, Hollander NH. Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO). Radiat Oncol. 2019 Jan 10;14(1):3. doi: 10.1186/s13014-019-1209-0. PMID 30630502